BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND HRAS, K-ras, 3265, ENSG00000174775, HRAS1, RASH1, c-bas/has, P01112, N-ras
1547 results:

  • 1. Myotubularin-related-protein-7 inhibits mutant (G12V) k-ras by direct interaction.
    Weidner P; Saar D; Söhn M; Schroeder T; Yu Y; Zöllner FG; Ponelies N; Zhou X; Zwicky A; Rohrbacher FN; Pattabiraman VR; Tanriver M; Bauer A; Ahmed H; Ametamey SM; Riffel P; Seger R; Bode JW; Wade RC; Ebert MPA; Kragelund BB; Burgermeister E
    Cancer Lett; 2024 Apr; 588():216783. PubMed ID: 38462034
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. A pH-responsive cetuximab-conjugated DMAKO-20 nano-delivery system for overcoming k-ras mutations and drug resistance in colorectal carcinoma.
    Song H; Li H; Shen X; Liu K; Feng H; Cui J; Wei W; Sun X; Fan Q; Bao W; Zhou H; Qian L; Nie H; Cheng X; Du Z
    Acta Biomater; 2024 Mar; 177():456-471. PubMed ID: 38331131
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors.
    Baranyi M; Molnár E; Hegedűs L; Gábriel Z; Petényi FG; Bordás F; Léner V; Ranđelović I; Cserepes M; Tóvári J; Hegedűs B; Tímár J
    Br J Cancer; 2024 Apr; 130(6):1059-1072. PubMed ID: 38278976
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Sotorasib Is a Pan-rasG12C Inhibitor Capable of Driving Clinical Response in NRASG12C cancers.
    Rubinson DA; Tanaka N; Fece de la Cruz F; Kapner KS; Rosenthal MH; Norden BL; Barnes H; Ehnstrom S; Morales-Giron AA; Brais LK; Lemke CT; Aguirre AJ; Corcoran RB
    Cancer Discov; 2024 May; 14(5):727-736. PubMed ID: 38236605
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Clinical-Molecular characteristics and Post-Translational modifications of colorectal cancer in north China: Implications for future targeted therapies.
    Chi Y; Yuan H; Fan Q; Wang Z; Niu Z; Yu J; Yuan D
    Gene; 2024 Mar; 899():148134. PubMed ID: 38185290
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Targeted Mass Spectrometry Analyses of Somatic Mutations in colorectal cancer Specimens Using Differential Ion Mobility.
    Wu Z; Bonneil É; Belford M; Boeser C; Dunyach JJ; Thibault P
    J Proteome Res; 2024 Feb; 23(2):644-652. PubMed ID: 38153093
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. An Alternative to Cytology in Triaging Cisgender Men and Transgender Women With HIV for High-Resolution Anoscopy.
    Mudrinich SM; Nguyen MLT; Blemur DM; Wang X; Wang YF; Krishnamurti U; Mosunjac M; Flowers LC
    J Low Genit Tract Dis; 2024 Jan; 28(1):101-106. PubMed ID: 38117565
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Surgeon-Dependent Variability in Cost of Gastrointestinal Operations in a Single cancer Center.
    Sarkar J; Roehner RP; Proulx MJ; Schwarz RE
    J Surg Res; 2024 Mar; 295():666-672. PubMed ID: 38113610
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Comprehensive analysis of miRNA-mRNA regulatory pairs associated with colorectal cancer and the role in tumor immunity.
    Liu C; Yu C; Song G; Fan X; Peng S; Zhang S; Zhou X; Zhang C; Geng X; Wang T; Cheng W; Zhu W
    BMC Genomics; 2023 Nov; 24(1):724. PubMed ID: 38036953
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Characteristic Mutational Damages in Gastric and colorectal Adenocarcinomas.
    Yermekova S; Orazgaliyeva M; Goncharova T; Rakhimbekova F; Kaidarova D; Shatkovskaya O
    Asian Pac J Cancer Prev; 2023 Nov; 24(11):3939-3947. PubMed ID: 38019254
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Oncologic relevance of genetic alterations in sporadic synchronous and solitary colorectal cancer: a retrospective multicenter study.
    Son IT; Kim M; Oh BY; Kim MJ; Yoon SN; Park JH; Kim BC; Kim JW
    BMC Gastroenterol; 2023 Sep; 23(1):297. PubMed ID: 37667167
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Small molecular inhibitors for KRAS-mutant cancers.
    Wu X; Song W; Cheng C; Liu Z; Li X; Cui Y; Gao Y; Li D
    Front Immunol; 2023; 14():1223433. PubMed ID: 37662925
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Ferroptosis-Mediated Cell Death Induced by NCX4040, The Non-Steroidal Nitric Oxide Donor, in Human colorectal cancer Cells: Implications in Therapy.
    Sinha BK; Bortner CD; Jarmusch AK; Tokar EJ; Murphy C; Wu X; Winter H; Cannon RE
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371096
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Evaluation of
    Lastraioli E; Bettiol A; Iorio J; Limatola E; Checcacci D; Parisi E; Bianchi C; Arcangeli A; Iannopollo M; Di Costanzo F; Di Lieto M
    Cells; 2023 May; 12(11):. PubMed ID: 37296579
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study.
    Goktas Aydin S; Kavak EE; Topcu A; Bayramgil A; Akgul F; Kahraman S; Aykan MB; Altıntas YE; Helvaci K; Urun Y; Bilici A; Seker M; Sendur MAN; Olmez OF; Acikgoz O; Cicin I
    Biomol Biomed; 2023 Nov; 23(6):1089-1095. PubMed ID: 37289436
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. KRAS Pathways: A Potential Gateway for cancer Therapeutics and Diagnostics.
    Tripathi PK; Mittal KR; Jain N; Sharma N; Jain CK
    Recent Pat Anticancer Drug Discov; 2024; 19(3):268-279. PubMed ID: 37038676
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Feedback activation of EGFR/wild-type RAS signaling axis limits KRAS
    Feng J; Hu Z; Xia X; Liu X; Lian Z; Wang H; Wang L; Wang C; Zhang X; Pang X
    Oncogene; 2023 May; 42(20):1620-1633. PubMed ID: 37020035
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Combinatorial Network of Transcriptional and miRNA Regulation in colorectal cancer.
    Kumar R; Mahmoud MM; Tashkandi HM; Haque S; Harakeh S; Ponnusamy K; Haider S
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982429
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Early evaluation of liver metastasis using spectral CT to predict outcome in patients with colorectal cancer treated with FOLFOXIRI and bevacizumab.
    Li S; Yuan L; Yue M; Xu Y; Liu S; Wang F; Liu X; Wang F; Deng J; Sun Q; Liu X; Xue C; Lu T; Zhang W; Zhou J
    Cancer Imaging; 2023 Mar; 23(1):30. PubMed ID: 36964617
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. DAB2IP Is a Bifunctional Tumor Suppressor That Regulates Wild-Type RAS and Inflammatory Cascades in KRAS Mutant Colon cancer.
    Miller AL; Perurena N; Gardner A; Hinoue T; Loi P; Laird PW; Cichowski K
    Cancer Res; 2023 Jun; 83(11):1800-1814. PubMed ID: 36939385
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 78.